FORM 51-102F3
MATERIAL CHANGE REPORT

1. Name and Address of Company

Ventripoint Diagnostics Ltd. (the "**Company**")
18 Hook Avenue, Unit 101
Toronto, ON
M6P 1T4

2. Date of Material Change

August 19, 2024.

3. News Release

On August 21, 2024, a news release was issued and disseminated through the facilities of a recognized newswire service.

4. Summary of Material Change

The material change is fully described in the Company's press release which is attached as Schedule "A" and is incorporated herein.

5. Full Description of Material Change

A description of the material change is contained under Item 4.

6. Reliance on subsection 7.1(2) of National Instrument 51-102

The report is not being filed in reliance on section 7.1(2) of National Instrument 51-102.

7. Omitted Information

No information has been omitted.

8. Executive Officer

The name of the executive officer of the Company who is knowledgeable about the material change and this report is:

Dr. George Adams, Executive Chairman, Director
Tel: (519) 803-6937
Email: gadams@ventripoint.com

9. Date of Report

August 22, 2024.

SCHEDULE "A"

PRESS RELEASE

Ventripoint Receives Medical Device License from Health Canada to Sell Next Generation, AI-powered, Heart-scanning Technology

Toronto, Ontario (August 21, 2024) - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) a leader in whole heart analysis, is pleased to announce that it has received a Medical Device License from Health Canada for its latest product offering, VMS+4.0. This is a major milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to cardiac clinicians worldwide.

VMS+4.0 offers a significant improvement in user experience through the automation of the image processing steps. This streamlined workflow leads to a significant reduction in operator time without compromising the accuracy of the measurements. Additionally, this release is optimized to work seamlessly with Ventripoint's recently announced magnet-free sensors, further enhancing efficiency, ease of use and applicability.

"We are delighted to receive the license and will immediately introduce the enhanced capabilities of the new version to Canadian cardiologists and healthcare providers," said Ventripoint President and CEO, Hugh MacNaught. "The advances introduced in VMS+4.0 enable its use for patients with intracardiac devices such as pacemakers and defibrillators, who cannot go into an MRI. This engineering breakthrough enlarges our market opportunity as it now empowers healthcare providers with a powerful tool that delivers accurate and reliable cardiac measurements in a more efficient manner and without the restrictions associated with MRI."

VMS+4.0 will be marketed as a premium product in Canada to complement our base product VMS+3.0, which has already received regulatory clearances from US-FDA, Health Canada, the United Kingdom (U.K.) and the European Union (E.U.) and is being used by leading hospitals in the U.S., E.U., U.K. and Canada.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition,

VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.